{"nctId":"NCT00435370","briefTitle":"Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia","startDateStruct":{"date":"2006-11"},"conditions":["Smoking Cessation","Schizophrenia"],"count":179,"armGroups":[{"label":"Tropisetron","type":"EXPERIMENTAL","interventionNames":["Drug: Tropisetron","Drug: Risperidone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Risperidone"]}],"interventions":[{"name":"Tropisetron","otherNames":["Navoban"]},{"name":"Placebo","otherNames":[]},{"name":"Risperidone","otherNames":["Risperdal, Ridal, Rispolept"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Currently resides in Beijing, China\n* Diagnosis of schizophrenia or schizophreniform disorder\n* Duration of symptoms is no longer than 60 months\n* No history of treatment with antipsychotic medication or, if previously treated, a total lifetime usage of less than 14 days\n* Current psychotic symptoms are of moderate severity or greater as measured by one of the five psychotic items in the Brief Psychiatric Rating Scale (BPRS)\n\nExclusion Criteria:\n\n* Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV Axis I diagnosis other than schizophrenia or schizophreniform psychosis\n* Documented disease of the central nervous system that might interfere with the trial assessments (e.g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic infection)\n* Acute, unstable, and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension)\n* A clinically significant echocardiogram (ECG) abnormality in the opinion of the investigator\n* Pregnant or breastfeeding\n* Use of prohibited concomitant therapy\n* History of severe allergy or hypersensitivity\n* Dependence on alcohol or illegal drugs\n* Use of any of the following medications during the trial: antipsychotic medications other than risperidone; psychostimulants; or antidepressants","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains","description":"The following 8 scales are combined into a single index that is normalized with a mean score of 100 and a standard deviation of 10. Higher scores are considered better cognitive performance. No subscales scores are reported and a final standardized score is reported as the average of the standardized scores on each of these scales. Here is the listing of component scales that were translated into Chinese and used for this study:\n\nBrief Assessment of Cognition in Schizophrenia (BACS): Symbol-Coding Trail Making Test: Part A Attention/Vigilance Continuous Performance Test-Identical Pairs (CPT-IP)\\* Wechsler Memory Scale®-3rd Ed. (WMS®-III): Spatial Span + Letter-Number Span Hopkins Verbal Learning Test-Revised™ (HVLT-R™) Brief Visuospatial Memory Test-Revised (BVMT-R™) Neuropsychological Assessment Battery® (NAB®): Mazes\n\nMayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT™):","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":"16"},{"groupId":"OG001","value":"95","spread":"15"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":90},"commonTop":["Other Adverse Event"]}}}